News and Announcements
Actinogen Expected to Treat First Patient Within Weeks
- Published April 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX: ACW) is pleased to provide a summary of its progress over the quarter ended 31 March 2017.
KEY TAKEAWAYS:
- Significant progress achieved with XanADu, Actinogen Medical’s Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
- 17 of a total planned 20 trial sites globally have been selected, with four of these actively recruiting patients.
- Treatment of first patient expected to start within weeks.
- XanADu represents a landmark in the global search for an effective treatment for Alzheimer’s disease and reinforces Australia’s role at the forefront of Alzheimer’s disease research.
- Recruitment follows regulatory approval received for XanADu in the US, the UK and Australia during the quarter.
- Healthcare industry and venture capital veteran, Dr Geoff Brooke, appointed as Chairman.
- Cash at 31st March 2017 of $5.2 million.
Actinogen Medical has made significant progress during the quarter with XanADu and expects to recruit the first patients for this landmark trial within weeks.
The Company remains focused on ensuring the trial progresses as expected and looks forward to updating the market on its progress over the near to medium term. Topline trial results are expected in early 2019.
“We have made excellent progress over the past few months with XanADu and expect to announce the successful recruitment of the first patient imminently. This ground breaking trial shows that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease,” said Dr Bill Ketelbey, CEO of Actinogen Medical.
“The development of Xanamem could potentially be one of the most significant contributions Australian clinical development will make to the management of Alzheimer’s disease- a disease presenting as the next major global health challenge for which new treatments are desperately needed.”
Actinogen Medical (ASX:ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic disease. Actinogen medical is developing Xanamem™ a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
